Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PINNACLE: Perioperative Pembrolizumab and Chemotherapy for Recurrent Nasopharyngeal Carcinoma
NCT07129772Phase 2Not yet recruiting
- Sponsor
- The University of Hong Kong
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in nasopharyngeal carcinoma (NPC), sponsored by The University of Hong Kong. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07129772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129772.